The Manila Times

EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Childre…

EURneffy 1 mg will be the first and only needle-free adrenaline available to younger children in the European Union ...

EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥ ...

EURneffy 1 mg will be the first and only needle-free adrenaline available to younger children in the European UnionARS Pharma’s partner, ...

California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use

California joins 23 other states eligible to receive free neffy ® (epinephrine nasal spray) at schoolsSAN DIEGO, (GLOBE NEWSWIRE) ...
KFGO

US FDA declines to approve Aquestive’s oral drug for allergic reactions

Aquestive Therapeutics said on Monday the U.S. FDA has declined to approve its oral drug for severe allergic reactions due to ...
manilatimes

California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use

SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect ...

OPINION: Health care isn’t a luxury. It’s foundational.

Health care isn’t a luxury. It’s foundational. It determines whether people can work, raise healthy families, and stay rooted ...

TempraMed Launches New Product "VIVI Med(TM)," Unlocking New Growth Opportunities in High-Value Biologics and Injectable Medications

Using same proprietary, patented technology, VIVI Med extends the product portfolio beyond injectable pens, opening access to broader patient populations, premium biologics, and institutional ...

Aquestive Therapeutics, Inc. (AQST) Discusses FDA Complete Response Letter and Next Steps for Anaphylm Epinephrine Sublingual Film Transcript

Discusses FDA Complete Response Letter and Next Steps for Anaphylm Epinephrine Sublingual Film February 2, 2026 8:00 ...
The American Journal of Managed Care

FDA Flags Administration Concerns for Aquestive's Noninvasive Epinephrine Film

Aquestive Therapeutics announced it received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application (NDA) for Anaphylm (dibutepinephrine) Sublingual Film, a noninvasive ...